XML 81 R64.htm IDEA: XBRL DOCUMENT v3.25.1
Note 13 - Segments - Schedule of Segment Reporting (Details) - USD ($)
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Rental income $ 18,523,813 $ 17,392,397
Fees and other income 401,462 243,217
Total revenue 18,925,275 17,635,614
Rental operating costs 6,256,077 5,962,918
General and administrative 7,526,675 6,790,432
Depreciation and amortization 5,515,518 5,425,739
Asset Impairment Charges 1,969,311 3,247,097
Total costs and expenses 21,267,581 21,426,186
Interest and other income, net (151,356) 1,435,298
Net loss in Conduit Pharmaceuticals marketable securities (see footnote 9) (17,925,723) (23,359,774)
Gain on deconsolidation of SPAC (see footnote 9) 0 40,321,483
Gain on sales of real estate, net 3,426,572 3,240,200
Income tax (expense) benefit (60,855) 335,780
Total other (loss) income, net (20,761,558) 16,968,098
Net (loss) income (23,103,864) 13,177,526
Less: Income attributable to noncontrolling interests (2,524,665) (3,031,080)
Net (loss) income attributable to Presidio Property Trust, Inc. stockholders (25,628,529) 10,146,446
Mortgage Notes [Member]    
Interest expense - mortgage notes (6,050,196) (5,004,889)
Operating Segments [Member] | Retail Properties [Member]    
Rental income 2,058,622 1,881,780
Fees and other income 62,041 2,550
Total revenue 2,120,663 1,884,330
Rental operating costs 608,667 537,389
General and administrative 0 0
Depreciation and amortization 394,461 456,277
Asset Impairment Charges 0 0
Total costs and expenses 1,003,128 993,666
Interest and other income, net 0 0
Net loss in Conduit Pharmaceuticals marketable securities (see footnote 9) 0 0
Gain on deconsolidation of SPAC (see footnote 9) 0 0
Gain on sales of real estate, net 0 0
Income tax (expense) benefit 0 0
Total other (loss) income, net (577,761) (588,405)
Net (loss) income 539,774 302,259
Less: Income attributable to noncontrolling interests 0 0
Net (loss) income attributable to Presidio Property Trust, Inc. stockholders 539,774 302,259
Operating Segments [Member] | Retail Properties [Member] | Mortgage Notes [Member]    
Interest expense - mortgage notes (577,761) (588,405)
Operating Segments [Member] | Office/Industrial Properties [Member]    
Rental income 12,097,022 11,367,853
Fees and other income 241,530 207,102
Total revenue 12,338,552 11,574,955
Rental operating costs 6,136,564 5,901,042
General and administrative 2,330 18,691
Depreciation and amortization 4,154,769 3,912,202
Asset Impairment Charges 1,377,937 1,966,113
Total costs and expenses 11,671,600 11,798,048
Interest and other income, net (171,734) 0
Net loss in Conduit Pharmaceuticals marketable securities (see footnote 9) 0 0
Gain on deconsolidation of SPAC (see footnote 9) 0 0
Gain on sales of real estate, net 0 0
Income tax (expense) benefit 0 0
Total other (loss) income, net (3,629,094) (2,744,996)
Net (loss) income (2,962,142) (2,968,089)
Less: Income attributable to noncontrolling interests (86,686) (94,500)
Net (loss) income attributable to Presidio Property Trust, Inc. stockholders (3,048,828) (3,062,589)
Operating Segments [Member] | Office/Industrial Properties [Member] | Mortgage Notes [Member]    
Interest expense - mortgage notes (3,457,360) (2,744,996)
Operating Segments [Member] | Model Home Properties [Member]    
Rental income 4,368,169 4,142,764
Fees and other income 68,084 (10,635)
Total revenue 4,436,253 4,132,129
Rental operating costs 171,621 156,493
General and administrative 820,217 865,368
Depreciation and amortization 952,627 1,015,691
Asset Impairment Charges 406,374 431,984
Total costs and expenses 2,350,839 2,469,536
Interest and other income, net (23,890) (27,775)
Net loss in Conduit Pharmaceuticals marketable securities (see footnote 9) 0 0
Gain on deconsolidation of SPAC (see footnote 9) 0 0
Gain on sales of real estate, net 3,426,572 3,240,200
Income tax (expense) benefit (55,543) 400,464
Total other (loss) income, net 1,337,498 1,944,034
Net (loss) income 3,422,912 3,606,627
Less: Income attributable to noncontrolling interests (2,437,979) (2,936,580)
Net (loss) income attributable to Presidio Property Trust, Inc. stockholders 984,933 670,047
Operating Segments [Member] | Model Home Properties [Member] | Mortgage Notes [Member]    
Interest expense - mortgage notes (2,009,641) (1,668,855)
Segment Reporting, Reconciling Item, Corporate Nonsegment [Member]    
Rental income 0 0
Fees and other income 29,807 44,200
Total revenue 29,807 44,200
Rental operating costs (660,775) (632,006)
General and administrative 6,704,128 5,906,373
Depreciation and amortization 13,661 41,569
Asset Impairment Charges 185,000 849,000
Total costs and expenses 6,242,014 6,164,936
Interest and other income, net 44,268 1,463,073
Net loss in Conduit Pharmaceuticals marketable securities (see footnote 9) (17,925,723) (23,359,774)
Gain on deconsolidation of SPAC (see footnote 9) 0 40,321,483
Gain on sales of real estate, net 0 0
Income tax (expense) benefit (5,312) (64,684)
Total other (loss) income, net (17,892,201) 18,357,465
Net (loss) income (24,104,408) 12,236,729
Less: Income attributable to noncontrolling interests 0 0
Net (loss) income attributable to Presidio Property Trust, Inc. stockholders (24,104,408) 12,236,729
Segment Reporting, Reconciling Item, Corporate Nonsegment [Member] | Mortgage Notes [Member]    
Interest expense - mortgage notes $ (5,434) $ (2,633)